Ambros Therapeutics launches with $125M to advance neridronate, a non-opioid therapy for CRPS-1. See how this Phase 3-ready ...

Pittsburgh Steelers head coach Mike Tomlin details the type of preparation required to be ready to face the Baltimore Ravens ...

Myanmar's junta said slightly more than half of eligible voters cast their ballot in the first phase of a three-stage ...

Young firms want walkable lanes, flexible workspaces, good public transport, places to eat at odd hours, and a feeling of ...

Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Invest in for the Next 3 Years. On December 12, Eli Lilly and ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) ...

Zenas's strong balance sheet, with $301.6M in cash and runway into late 2026, supports aggressive late-stage pipeline ...

The latest announcement is out from Ultragenyx Pharmaceutical ( ($RARE) ). On December 29, 2025, Ultragenyx reported Phase 3 results from its ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

GeeFi's presale continues its impressive run as Phase 3 kicks off with immediate strength, raising over $180,000 shortly ...

Theriva Biologics ( ($TOVX) ) just unveiled an update. On December 29, 2025, Theriva Biologics reported that it received positive Scientific ...

Investing.com -- Theriva Biologics Inc (NYSE American:TOVX) stock surged 25.4% in Monday premarket trading after the company announced receiving positive scientific advice from the European Medicines ...